TransAlta (NYSE:TAC) 2026 Investor Day March 23, 2026 09:00 AM ET Company ParticipantsBen Harris - Manager of Investor RelationsBen Pham - Managing DirectorChris Fralick - EVP of GenerationJoel Hunter - EVP of Finance and CFOJohn Kousinioris - President and CEOJohn Mould - Managing DirectorMark Jarvi - Managing DirectorMaurice Choy - Managing DirectorRobert Hope - Managing DirectorStephanie Paris - VP of Investor Relations and Corporate StrategyStephanie ParisGood morning, everyone and welcome to TransAlta' ...

Delivery Hero Taiwan Divestment Conference Call Summary Company Overview - **Company**: Delivery Hero (OTCPK:DELH.Y) - **Event**: Taiwan Divestment Conference Call - **Date**: March 23, 2026 Key Points Industry and Company Context - Delivery Hero is undergoing a strategic review, with the divestment of its food delivery operations in Taiwan to Grab for **$600 million** in cash, marking a significant milestone in its strategy [3][2] - The Taiwan business generated a **GMV of EUR 1.5 billion** in full year 2025, accounting for approximately **3%** of the group's total GMV [5] Financial Implications - The divestment will reduce Delivery Hero's net leverage from approximately **2.7 times to 2.2 times**, strengthening its capital structure [5] - The transaction is expected to close in the **second half of 2026**, pending regulatory approvals [5] - Delivery Hero will provide support services for a migration period of up to **12 months** post-transaction [5] Operational Performance - The Taiwan business was noted to have a positive EBITDA before central costs, with the impact of its loss on overall EBITDA expected to be marginal for 2026 [14] - The company anticipates that the transition services will not significantly affect cash flow or EBITDA during the support period [14] Market Position and Competitiveness - Delivery Hero holds a strong market position in Taiwan, having improved profitability over recent years [32] - The competitive landscape includes Uber, with varying strengths in different geographical areas [32] Strategic Rationale - The divestment is part of a broader strategy to optimize the company's asset portfolio and focus on core operations [3] - The management emphasized the importance of maintaining flexibility and being prepared for future opportunities or challenges [10] Future Outlook - The company is not providing interim updates on other ongoing reviews to protect the integrity of the processes [5] - The management expressed confidence in the deal's value for both Delivery Hero and Grab, indicating a favorable market environment for the transaction [24] Additional Insights - The issuance of a **$1.4 billion** term loan prior to the divestment raised questions among investors regarding the need for such a substantial cash balance [8] - The management clarified that the term loan was aimed at repaying existing debt and strengthening the capital structure [10] This summary encapsulates the critical aspects of the Delivery Hero conference call, highlighting the strategic divestment, financial implications, operational performance, and market positioning within the food delivery industry.

Ecolab's Acquisition of CoolIT Systems Conference Call Summary Company and Industry Overview - **Company**: Ecolab - **Acquisition Target**: CoolIT Systems - **Acquisition Value**: $4.75 billion - **Expected Closing**: Q3 2026 - **Industry**: Water technology and services, specifically focused on data centers and microelectronics Key Points and Arguments Acquisition Details - Ecolab has entered into a firm agreement to acquire CoolIT Systems for $4.75 billion, expected to close in Q3 2026, pending customary approvals [3][18] - The acquisition is seen as a strategic move to enhance Ecolab's capabilities in the high-tech water business, particularly in cooling technologies for data centers [3][10] Financial Performance Expectations - Ecolab anticipates adjusted EPS for Q1 2026 to be between $1.69 and $1.71, reflecting a year-over-year growth of 13%-14% [4] - For the full year 2026, excluding CoolIT, Ecolab expects 12%-15% adjusted EPS growth [4][68] - The acquisition of CoolIT is projected to lift Ecolab's total organic sales growth by more than one percentage point starting one year after the close [15] Growth Projections - Ecolab aims for an operating income margin of over 20% by 2027, driven by strong growth in high-margin businesses and innovation [6] - The company expects to achieve 5%-7% organic sales growth, supported by the addition of CoolIT [6][24] Market Dynamics - The liquid cooling market is projected to grow at over 30% annually, with an addressable market reaching approximately $50 billion by 2035 [12] - CoolIT is positioned as a leader in direct-to-chip liquid cooling, currently holding a double-digit market share in North America [13][14] Strategic Synergies - Ecolab plans to leverage CoolIT's technology to enhance its existing offerings, particularly through the integration of 3D TRASAR technology for optimized cooling performance [44][45] - The combined capabilities are expected to create a differentiated end-to-end cooling platform, enhancing customer value and operational efficiency [16][22] Recurring Revenue Model - Ecolab maintains a strong recurring revenue model, with expectations that 90% of its revenue will remain recurring post-acquisition [29][31] - The integration of CoolIT is expected to enhance this model by providing additional consumables and services tied to new technologies [30][31] Capacity and Investment - CoolIT currently has the capacity to double its sales, and Ecolab plans to maintain its existing CapEx model while investing in growth [54][56] - The acquisition is expected to be accretive to Ecolab's long-term sales and EPS growth algorithm, with a focus on maintaining a strong investment-grade profile [17][68] Additional Important Insights - Ecolab's growth strategy is heavily influenced by the increasing demand for AI and data center capabilities, with a focus on water management and cooling solutions [10][81] - The acquisition aligns with Ecolab's historical approach to strategic M&A, focusing on high-return businesses that compound value over time [24] - Ecolab's leadership emphasizes the importance of technology and innovation in driving growth and maintaining competitive advantages in the market [40][41] This summary encapsulates the key points discussed during the conference call regarding Ecolab's acquisition of CoolIT Systems, highlighting the strategic importance, financial expectations, and market dynamics surrounding the deal.

Apogee Therapeutics Conference Call Summary Company Overview - **Company**: Apogee Therapeutics (NasdaqGM:APGE) - **Focus**: Development of treatments for atopic dermatitis and type two inflammation Industry Context - **Market Size**: Atopic dermatitis is projected to become the largest I&I market, potentially exceeding $50 billion [4][32] - **Current Treatments**: Limited options exist, with even modestly differentiated products achieving blockbuster status [4] Key Points from the Call Clinical Development and Results - **Drug**: Zumilokibart (Zumi) - **Study**: APECS Part A 52-week maintenance results - **Efficacy**: - 75% maintenance of EASI-75 response with 3-month dosing - 85% maintenance of EASI-75 response with 6-month dosing - 86% maintenance of IGA 0/1 response with 3-month dosing - 78% maintenance of IGA 0/1 response with 6-month dosing [5][12] - **Deepening Responses**: Observed across all endpoints tested, contrasting with Dupixent, which plateaued after week 16 [6][15] - **Safety Profile**: Well-tolerated with adverse events consistent with the IL-13 class, including a 20.2% rate of non-infective conjunctivitis [11][25] Market Opportunity - **Unmet Need**: Significant quality-of-life impact for patients with atopic dermatitis, including sleep loss and mood disorders [21][22] - **Dosing Advantage**: Zumi offers a reduced injection burden (2-4 times per year) compared to standard care (26 times per year) [31][32] - **Potential Launch**: Planned for 2029, with expectations of becoming a first-line treatment option [29][32] Future Directions - **Phase III Trials**: On track to initiate in the second half of the year, with part B results expected in Q2 2026 [29][33] - **Expansion Potential**: Zumi's application may extend to asthma and eosinophilic esophagitis, with positive phase I-B asthma data already disclosed [29] Competitive Landscape - **Comparison with Other Treatments**: Zumi's efficacy and safety profile position it favorably against existing treatments like Dupixent and JAK inhibitors [72] - **Market Penetration**: Atopic dermatitis remains underpenetrated, with new entrants quickly achieving blockbuster status [32] Conclusion - **Strategic Vision**: Apogee aims to establish itself as a leader in the I&I market by delivering innovative treatments that address significant unmet needs in atopic dermatitis [32][34]

Summary of Grab's Acquisition of Foodpanda Taiwan Conference Call Company and Industry - **Company**: Grab (NasdaqGS:GRAB) - **Industry**: Food Delivery Services Key Points and Arguments Acquisition Announcement - Grab announced the acquisition of Delivery Hero's Foodpanda delivery business in Taiwan for **$600 million** in an all-cash transaction, marking Grab's entry into its **ninth market** and first outside Southeast Asia [4][19] Strategic Rationale - **Cultural Familiarity**: The CEO emphasized the cultural ties between Taiwan and Southeast Asia, which will facilitate better understanding of local users [5] - **Urban Density**: Taiwan's urban density is **3.6 times** larger than the Southeast Asian average, allowing for more efficient delivery operations [6] - **Spending Power**: Taiwan is the highest income market outside Singapore, with **70%** of users already using food delivery apps by 2025 [6] - **Demographics**: Over **40%** of households in Taiwan are single-person residences, indicating a strong demand for food delivery services [6] Market Potential - Taiwan's economy grew **9%** in 2025, the strongest growth in 15 years, driven by exports and AI demand [8] - The central bank raised its 2026 GDP growth forecast to **7%**, indicating robust economic conditions [9] - Foodpanda Taiwan generated **$1.8 billion** in GMV across 21 cities in 2025, with a user penetration of just **10%**, suggesting significant growth potential [10] Financial Projections - The acquisition is expected to add over **$40 billion** to Grab's existing **$200 billion** addressable market in Southeast Asia, increasing the total to **$240 billion** [11] - The Foodpanda Taiwan business is projected to contribute at least **$60 million** in incremental Adjusted EBITDA by 2028 [21] Integration and Operational Strategy - Grab plans to migrate users and partners from the Foodpanda app to the Grab app by early 2027, with a focus on leveraging AI tools to enhance partner earnings [19][20] - The integration will involve front-loaded costs, but profitability is expected by the end of 2027 [27] Competitive Landscape - Grab aims to improve driver earnings while reducing consumer prices, a strategy that has proven successful in Southeast Asia [17] - The acquisition positions Grab in direct competition with Uber, which holds a **14%** stake in Grab, but the CEO emphasized a commitment to all shareholders [40] Regulatory Considerations - Grab is committed to building strong relationships with Taiwanese regulators, differentiating this acquisition from previous failed attempts by Uber [38] Future Outlook - Grab remains focused on expanding its presence in Southeast Asia while exploring inorganic growth opportunities like the Taiwan acquisition [36] - The company is also addressing rising fuel prices through targeted subsidies and a transition to electric vehicles (EVs) [44][45] Additional Important Information - The acquisition is seen as a disciplined, strategic move consistent with Grab's growth strategy over the past eight years [21] - The company has a proven integration playbook from previous acquisitions, which will be applied to the Taiwan market [21] This summary encapsulates the key points from Grab's conference call regarding the acquisition of Foodpanda Taiwan, highlighting the strategic rationale, market potential, financial projections, and operational strategies.

Summary of Insmed Phase IIIb ENCORE Study Conference Call Company and Industry - **Company**: Insmed - **Industry**: Pharmaceutical, specifically focusing on treatments for MAC (Mycobacterium avium complex) lung infections Core Points and Arguments 1. **Study Success**: The ENCORE trial demonstrated a statistically significant improvement in respiratory symptom scores for patients treated with ARIKAYCE compared to the placebo group, indicating its effectiveness in treating MAC lung infections [4][10] 2. **Culture Conversion**: The study showed that 82.4% of patients in the ARIKAYCE arm achieved culture conversion by month 13, compared to 55.6% in the control arm, with a highly significant difference of approximately 27 percentage points [14][15] 3. **Durability of Treatment**: The results indicated that the benefits of ARIKAYCE persisted even after treatment cessation, with 76.2% of patients maintaining culture conversion at month 15 [16][17] 4. **Regulatory Submissions**: Insmed plans to pursue regulatory submissions with the FDA and PMDA in the second half of the year, aiming to expand the label to include all patients with MAC lung infections, increasing the addressable patient population from around 30,000 to over 200,000 [6][22] 5. **Safety Profile**: The safety profile of ARIKAYCE was consistent with previous studies, with no new safety signals observed. The treatment discontinuation rate was 18.3%, lower than previous studies, indicating improved tolerability [20][21] 6. **Patient-Reported Outcomes**: The study utilized a validated patient-reported outcome tool, which is a first in this disease state, enhancing the credibility of the findings [5][9] 7. **Market Potential**: The expansion of the patient population and the positive results from the study are expected to lead to significant revenue growth, with potential market penetration anticipated in the next 12-24 months [57][76] Other Important Content 1. **Comparison to Standard of Care**: The study aimed to establish a new standard of care by demonstrating that ARIKAYCE, when added to a two-drug regimen, provides significant benefits in both symptoms and culture conversion [25][26] 2. **Long-term Benefits**: While the study did not specifically assess survival benefits, the durable culture conversion suggests potential long-term advantages for patients, including reduced risk of becoming refractory to treatment [29][31] 3. **Dysphonia Rates**: Dysphonia was reported in 50.7% of patients in the ARIKAYCE arm, but measures to mitigate this side effect have been identified, enhancing the overall benefit-risk profile [36][37] 4. **Real-World Applicability**: The trial population is considered representative of real-world treatment practices, which may facilitate the adoption of ARIKAYCE in clinical settings [42][43] 5. **International Market**: Japan is highlighted as a significant market opportunity due to a higher prevalence of MAC infections, with expectations for continued revenue generation from this region [72][73] This summary encapsulates the key findings and implications from the conference call regarding the ENCORE study and the future of ARIKAYCE in treating MAC lung infections.

Veolia Environnement Update Summary Company Overview - **Company**: Veolia Environnement (OTCPK: VEOE.F) - **Date of Briefing**: March 23, 2026 Key Industry Insights - **Geopolitical Context**: The company operates in a world marked by geopolitical tensions, particularly in the Middle East, which affects global trade and emphasizes the importance of environmental security as a matter of national security and economic sovereignty [2][8]. - **ESG Relevance**: The current instability reinforces the relevance of Environmental, Social, and Governance (ESG) strategies, as environmental challenges are now seen as security imperatives [2]. Financial Performance - **Revenue**: Achieved over EUR 44 billion in revenue, with EBITDA up 6.3%, exceeding guidance [3]. - **Profitability**: Current net income increased by 11.8% on average per year over the past two years, with profitability up 150 basis points [3]. - **Gross Profit Target**: Achieved a gross profit target of 9.4% two years ahead of schedule [4]. - **Leverage Ratio**: Maintained a leverage ratio of 2.79 times, below the 3 times threshold, indicating financial strength [4]. - **International Operations**: EBITDA increased by 9.3% outside Europe, driven by hazardous waste and water technologies [4]. Environmental Performance - **GreenUp Plan**: Two out of three GreenUp objectives achieved two years early, including saving nearly 1.6 billion cubic meters of fresh water and treating 9.2 million tons of hazardous waste [5][24]. - **Decarbonization**: Scope 1 and 2 emissions reduced by 18.6% compared to 2021, with a target to reduce coal-based activity to below 1% by 2030 [10][12]. - **Biodiversity Initiatives**: Aiming to deploy biodiversity action plans on 85% of sensitive sites by 2027, having already reached 80% [26]. Operational Highlights - **Employee Engagement**: Achieved an 85% employee engagement rate, significantly above the utilities benchmark, with a focus on safety and security [31]. - **Safety Improvements**: Workplace accidents down 75% over 15 years, with a 5% reduction this year [32]. - **Employee Shareholding**: Aiming for 10% employee shareholding to enhance trust and ownership among employees [33]. Strategic Initiatives - **Decarbonization Strategy**: Integrated into the business model, focusing on methane capture, energy efficiency, and coal exit plans [10][12]. - **Water Resource Management**: Advanced tools deployed to monitor water distribution, aiming to save 1.5 billion cubic meters of freshwater by 2027 [24]. - **Hazardous Waste Management**: Achieved treatment of 9.2 million tons of hazardous waste, ahead of the 2027 target [25]. Market Opportunities - **AI and Digital Strategy**: AI is central to improving operational efficiency, with a significant increase in efficiency attributed to AI and digital initiatives [42]. - **Recycling and Circular Economy**: The EU's support for recycling aligns with Veolia's strategy to secure supply chains and reduce dependency on imports [51]. Regional Focus - **Middle East Operations**: Revenue from the Middle East is approximately EUR 1 billion, with a focus on essential services like desalination and hazardous waste management [50][46]. - **Coal Exit Plans**: Successful coal exit strategies in Central Eastern Europe are scalable to other regions, with a focus on multi-fuel approaches [54][56]. Conclusion - **Value Proposition**: Veolia's unique value proposition lies in delivering environmental security that creates lasting shareholder value, addressing critical challenges such as water scarcity and pollution [7][8]. - **Future Outlook**: The company is well-positioned to continue its growth trajectory, leveraging its integrated business model that aligns sustainability with profitability [37].

Helios Technologies 2026 Investor Day Summary Company Overview - **Company**: Helios Technologies (NYSE: HLIO) - **Event**: 2026 Investor Day held on March 20, 2026 - **Recent Financial Performance**: Reported 2025 results of $839 million, with a pro forma view of $792 million after a divestiture [7][8] Core Industry Insights - **Segments**: Helios operates in two main segments: Hydraulics and Electronics - **Revenue Distribution**: Electronics accounts for nearly 40% of total revenues; OEMs represent about 57% of sales channels [8][20] - **Market Dynamics**: The company has diversified end markets, reducing reliance on any single customer or market [22] Strategic Initiatives - **CORE 2030 Strategy**: Aims to double sales to $1.6 billion by 2030, with a commitment to 5% organic growth annually [48][52] - **Financial Goals**: Targeting adjusted EBITDA margins exceeding 25% and operating income margins of 20% [52] - **Product Development**: Launched 11 new products in 2025, contributing to incremental revenue streams [39] Leadership and Governance - **Leadership Changes**: Sean Bagan appointed as President and CEO in January 2025, emphasizing a disciplined approach to financial forecasting and strategic planning [10][13] - **Board Refreshment**: Over 70% of the board has been refreshed in the last five years, with Laura Dempsey Brown as the new chair [4][30] Financial Health - **Debt Management**: Significant progress in reducing debt, with $153 million paid down over two years, resulting in a leverage ratio below 2x [45] - **Shareholder Returns**: Initiated a share repurchase program, returning capital to shareholders at an average share price of $55 [46] Market Opportunities - **Electronics Segment Growth**: Focus on expanding in underserved markets, particularly in EMEA and APAC regions [60] - **Health and Wellness Market**: Balboa Water Group leads in health and wellness, with ongoing growth opportunities [64] Employee Engagement - **Employee Statistics**: Average tenure of 9 years, with a notable increase in employee net promoter score by 13 points [41] - **Talent Development**: Initiatives like the Helios Leadership Academy aim to cultivate the next generation of leaders [43] Challenges and Resilience - **Pandemic Impact**: Experienced organic sales declines and margin compression post-pandemic, but returned to growth after 12 quarters of decline [9][13] - **Crisis Management**: Successfully navigated local challenges, including hurricanes, which fostered organizational unity and resilience [11][12] Conclusion - **Future Outlook**: Helios Technologies is positioned for growth with a clear strategy, strong leadership, and a commitment to innovation and customer satisfaction [14][47]

Rhythm Pharmaceuticals Conference Call Summary Company Overview - **Company**: Rhythm Pharmaceuticals (NasdaqGM:RYTM) - **Product**: IMCIVREE (setmelanotide) - **Indication**: Approved for patients with acquired hypothalamic obesity Key Points FDA Approval and Product Details - The FDA has granted approval for IMCIVREE to treat acquired hypothalamic obesity, marking it as the first FDA-approved therapy targeting the underlying biology of this condition [2][4] - IMCIVREE is a melanocortin 4 receptor (MC4R) agonist indicated to reduce excess body weight and maintain long-term weight reduction in adults and pediatric patients aged 4 and older [6] - The approval was supported by the global phase 3 TRANSCEND trial, which showed a statistically significant placebo-adjusted difference of 18.4% in BMI reduction after 52 weeks of treatment [7] Clinical Trial Results - The trial included a total of 142 patients, with significant improvements in hunger scores observed: a 2.3-point reduction in the treatment group compared to a 1.4-point reduction in the placebo group [7] - The consistent response to MC4R agonists across trials reinforces the importance of the MC4R pathway in the biology of obesity [5][9] Market Opportunity - Approximately 10,000 patients in the U.S. are estimated to have acquired hypothalamic obesity, with about 500 new cases annually [12] - The approval is expected to drive increased diagnosis rates and treatment initiation, as there was previously no approved treatment for this condition [12][13] Sales and Marketing Strategy - Rhythm has expanded its sales team from 16 to 42 territory managers to engage with physicians and secure reimbursement for patients [13] - The company aims to educate healthcare providers about the condition and the new treatment option, facilitating quicker diagnoses and treatment initiation [15][51] Payer Engagement and Reimbursement - Rhythm is working to differentiate IMCIVREE from other anti-obesity medications to improve coverage prospects with payers, including Medicare [8][68] - The company plans to provide metrics on patient start forms, payer coverage, and physician engagement as part of their launch strategy [28] Future Developments - Rhythm is pursuing international opportunities and anticipates updates on its Japanese filing and EMEA submission for hypothalamic obesity in the coming quarters [9] - The company is also working on obtaining an ICD-10 code for hypothalamic obesity to facilitate diagnosis and treatment [56] Safety and Monitoring - The approval includes a warning for monitoring adrenal insufficiency, as a significant portion of patients may have hormonal deficiencies [80] - The FDA did not allow the inclusion of hyperphagia reduction in the indication statement, although it is noted in the clinical results section [82][86] Conclusion - The approval of IMCIVREE represents a significant milestone for patients with acquired hypothalamic obesity, providing a much-needed treatment option and addressing a high unmet need in this patient population [88]

Summary of Orion Engineered Carbons Conference Call Company Overview - **Company**: Orion Engineered Carbons (Ticker: OEC) - **Headquarters**: Luxembourg, executive offices in Spring, Texas - **Industry**: Carbon black manufacturing - **Market Position**: Leading global manufacturer and supplier of carbon black products, primarily rubber carbon black and specialty carbon black [1][2] Financial Highlights - **Shares Outstanding**: Approximately 56 million - **Market Cap**: $280 million - **Net Debt**: $918 million - **Enterprise Value**: $1.2 billion - **Recent Revenue**: EUR 1.8 billion - **EBITDA**: EUR 248 million - **Free Cash Flow**: EUR 55 million [2][9] Strategic Focus - **Free Cash Flow Generation**: Identified as the primary financial priority for 2026 and beyond, with a focus on improving cash flow through working capital actions and reduced capital expenditures [7][13] - **Debt Reduction**: Aiming to reduce net debt, which was approximately 3.7x net debt to EBITDA at year-end [14][41] Market Dynamics - **Rubber Carbon Black**: Represents two-thirds of the business, with a focus on tire applications (OEM and replacement tires) and mechanical rubber goods [16][17] - **Specialty Carbon Black**: Accounts for one-third of the business, with applications in polymers, coatings, and batteries [19][20] - **Growth Drivers**: Traditional growth driven by miles driven, tire production, and vehicle production, with emerging trends in sustainability and electric vehicle (EV) mobility [18][23] Pricing and Contracts - **Pricing Strategy**: A variable price surcharge of up to 25% was introduced, primarily affecting the specialty side of the business, as most rubber customers are under annual contracts [49][50] - **Market Conditions**: Anticipated challenges in pricing negotiations for 2026 due to high imports and late negotiation cycles [40][41] Production Capacity and Regional Focus - **Capacity Utilization**: Estimated at mid-80s percentage for effective capacity utilization, with regional dynamics affecting supply [56] - **Local Supply Importance**: Emphasized the critical nature of being a local supplier to tire manufacturers in North America, especially given the lack of new carbon black capacity being built in the U.S. [35][36] Environmental and Regulatory Considerations - **EPA Investments**: Significant investments made in compliance with EPA regulations, with competitors still facing these costs, potentially benefiting Orion in terms of pricing and market position [37][38] Future Outlook - **2026 Projections**: Expected EBITDA between EUR 160 million and EUR 200 million, with free cash flow projected at EUR 25 million to EUR 50 million [42] - **Market Recovery**: Anticipated improvement in market conditions and pricing environment, driven by reduced capacity in the market and better economic indicators [34][41] Additional Insights - **Customer Relationships**: Strong relationships with global tire customers are expected to provide opportunities for spot volume [30] - **Safety and Reliability**: Achieved record safety performance, significantly better than industry average, contributing to operational reliability [39] This summary encapsulates the key points discussed during the conference call, highlighting Orion Engineered Carbons' market position, financial performance, strategic focus, and outlook for the future.